Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2019-02-28 Report Publication Anno…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces that Ipsen will present new data at the 16th annual conference of the European Neuroendocrine Tumor Society (ENETS). It details the abstracts and studies to be presented, focusing on product data (lanreotide/Somatuline® and Xermelo®) and research findings related to neuroendocrine tumors (NETs). This format—a formal announcement detailing upcoming scientific presentations, often including key data highlights and product information—is characteristic of an Investor Presentation (IP) or a general announcement related to investor/scientific communication. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT), and it is a detailed presentation of research findings intended for investors and the scientific community, 'Investor Presentation' (IP) is the most fitting category, even though it is presented as a press release announcing conference participation. It is more substantial than a simple RPA or RNS.
2019-02-28 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
M&A Activity Classification · 99% confidence The document is a press release announcing a major corporate action: Ipsen's acquisition of Clementia Pharmaceuticals. This transaction involves the purchase of all outstanding shares for a specific price, including contingent value rights (CVRs), and is framed as a strategic move to strengthen Ipsen's rare disease portfolio. This type of announcement, detailing a merger or takeover proposal, directly corresponds to the definition of M&A Activity (TAR). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a proxy statement (PSI). Since it is a detailed announcement of the transaction terms, it is classified as TAR rather than the general fallback (RNS).
2019-02-25 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
M&A Activity Classification · 98% confidence The document is explicitly titled "PRESS RELEASE" and announces a significant corporate action: Ipsen's acquisition of Clementia Pharmaceuticals. It details the terms of the transaction (purchase price, CVR), strategic rationale (boosting Rare Disease portfolio), expected regulatory milestones (NDA submission, potential approval), and updates on Ipsen's 2019 financial objectives. This content strongly aligns with an announcement regarding a major corporate transaction or financing activity, which falls under the Capital/Financing Update (CAP) category, as it involves a large cash transaction and changes to the capital structure/outlook. While it is a press release, it is not a standard Earnings Release (ER) or a general Regulatory Filing (RNS); it is specifically about a merger/acquisition, which is best classified as CAP, or potentially TAR (M&A Activity). Given the focus on the financing structure and the impact on financial guidance, CAP is a strong fit, but TAR (Merger/Takeover Activity) is the most precise fit for an acquisition announcement. I will select TAR.
2019-02-25 English
Information relating to the total number of voting rights and shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled 'Monthly information regarding the total number of voting rights and total number of shares of the Company' and explicitly references Article 223-16 of the AMF General Regulations. It provides a table detailing the total number of shares and total voting rights as of a specific date (January 31, 2019). This content directly relates to the official declaration of voting rights and share structure, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' category (DVA). It is not an AGM result (AGM-R) but a routine monthly disclosure of voting rights.
2019-02-20 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 223-16 of the AMF General Regulation (Autorité des Marchés Financiers) and provides a table detailing the total number of shares and voting rights as of January 31, 2019. This type of regular disclosure regarding the total share capital and voting rights structure is a standard regulatory filing, but it does not fit perfectly into the specific categories like DVA (which is for voting *results*), SHA (which is for *changes* like splits/issues), or POS (which is for treasury stock transactions). Since it is a mandatory, periodic disclosure about the capital structure and voting rights, and it is not a report announcement (RPA) or a general miscellaneous filing (RNS), the closest fit among the provided options that deals with capital structure reporting, although not perfectly aligned with the definition, is difficult. However, given the content is a mandatory disclosure about the total number of shares and voting rights, it is a specific regulatory disclosure. If we must choose from the list, and recognizing that this is a periodic disclosure about the capital base, it is most closely related to capital structure updates. Since 'SHA' is for 'Share Issue/Capital Change' and this is a periodic report *of* the capital structure, and 'RNS' is the general regulatory fallback, I will re-evaluate. The content is a mandatory disclosure of the total number of shares and voting rights, which is often required monthly in France. This is a specific regulatory filing. Given the options, and noting that it is not a change (SHA) nor a vote result (DVA), the most appropriate general regulatory category is RNS, as it is a mandatory regulatory filing that doesn't fit the other specific codes. However, if we consider the nature of the data (total shares/votes), it is a fundamental piece of capital information. Let's check the definitions again. None perfectly match a 'Total Voting Rights Disclosure'. Given the mandatory regulatory nature and lack of a better fit, RNS (Regulatory Filings - fallback) is the safest classification, although it is a very specific type of filing. Upon further review, this type of filing is often categorized under general regulatory disclosures when a specific code for 'Total Voting Rights' is absent. I will use RNS.
2019-02-20 French
Communiqués au titre de l'obligation d'information permanente / Information sur chiffre d’affaires annuel
Audit Report / Information Classification · 95% confidence The document text explicitly states that Ipsen 'a publié aujourd'hui ses résultats financiers pour l'année 2018' (published its financial results for the year 2018). It contains detailed financial tables (revenues, operating income, net income, EPS) for the full year 2018 compared to 2017, along with management commentary and forward-looking guidance for 2019. The content is comprehensive, covering the entire fiscal year's performance, which strongly indicates an Annual Report or a document closely related to it. Since the text includes 'Extrait des résultats consolidés audités des années 2018 et 2017' and provides the full scope of annual performance metrics, it aligns best with the Annual Report category (10-K), even if it might be an Earnings Release (ER) or Interim Report (IR) in a different context. However, the depth and focus on the full year's audited consolidated results point towards the annual reporting cycle. Given the options, and the comprehensive nature of the full-year financial review, 10-K is the most appropriate classification for a detailed annual financial disclosure, although ER is also plausible if this is the initial press release accompanying the 10-K filing. Since it contains detailed audited extracts and full-year analysis, it is more substantial than a typical ER. If this were a US filer, this would be the 10-K content. For a non-US filer, this detailed annual results announcement often serves the function of the 10-K. I will classify it as ER because it is presented as a press release dated February 14, 2019, announcing the 2018 results, which is the typical format for an Earnings Release (ER). The document length is substantial, suggesting it is more than just highlights, but the structure is that of a results announcement press release, not the formal 10-K filing itself. FY 2018
2019-02-14 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.